Ultragenyx

Ultragenyx

Yahoo Finance • 21 days ago

FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) just added another commercial product to its portfolio. The FDA on September 17 approved Fayuvi for the treatment of neurologic manifestations of Sanfilippo syndrome Type A in pediatric patients... Full story

Yahoo Finance • 24 days ago

How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI

In September 2026, Ultragenyx Pharmaceutical received full U.S. FDA approval for FAYUVI (UX111), the first-ever treatment for pediatric patients with Sanfilippo syndrome Type A, along with a Priority Review Voucher. This approval not only... Full story

Yahoo Finance • 25 days ago

Andelyn and Its Curator® Platform Achieve First FDA-Approved Commercial Gene Therapy Manufacturing Milestone Following FDA Approval of Ultragenyx's FAYUVITM to Treat Sanfilippo Syndrome Type A (MPS IIIA)

COLUMBUS, Ohio, Sept. 18, 2026 /PRNewswire/ -- Andelyn Biosciences ("Andelyn"), a leading, patient-focused cell and gene therapy Contract Development and Manufacturing Organization ("CDMO"), today announced it is now manufacturing FAYUVI™... Full story

Yahoo Finance • 25 days ago

Ultragenyx wins FDA approval for pediatric gene therapy for Sanfilippo syndrome

[Paper with words Sanfilippo syndrome and glasses.] * The US FDA has approved Ultragenyx Pharmaceutical's (RARE [https://seekingalpha.com/symbol/RARE]) gene therapy Fayuvi (rebisufligene etisparvovec) for pediatric treatment of Sanfilip... Full story

Yahoo Finance • last month

Nvidia, Tesla, Robinhood, Snowflake, Ultragenyx, Ciena, and More Stocks That Explain Today’s Market

Nvidia stock rises on a deal for it to acquire Hugging Face while Tesla sadvances ahead of an important Cybercab event. Continue Reading... Full story

Yahoo Finance • last month

Broadcom upgraded, Ultragenyx downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Macquarie upgraded Broadcom (AVGO) to... Full story

Yahoo Finance • last month

Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More

Quick Read Broadcom, Deere, and Dell all earned Outperform upgrades Thursday, with analyst price targets set at $490, $813, and $625 respectively. Moderna was cut to Sell with an $81 target, while Ultragenyx's price target was halved to $... Full story

Yahoo Finance • last month

Premarket movers: Snowflake, Five Below surge after strong earnings

Investing.com -- U.S. equity futures were mixed early Thursday, a day after major averages snapped a three-day losing streak driven by rising Treasury yields amid renewed U.S.-Iran hostilities. S&P 500 futures were up 0.1%, Dow futures ros... Full story

Yahoo Finance • last month

Ultragenyx drops on Phase 3 trial failure for Angelman syndrome drug

[Woman scientist in lab look at science microscope medical test and research biology chemistry. Females technician laboratory analyzing scientific pharmacy genetic research. Chemistry Medical test lab] howtogoto * Ultragenyx Pharmaceuti... Full story

Yahoo Finance • last month

Ultragenyx Pharmaceutical (RARE) Wins FDA Approval, Is The Stock Fully Priced?

Ultragenyx Pharmaceutical (RARE) recently received accelerated approval from the U.S. Food and Drug Administration for GENGLYCOS, a gene therapy for glycogen storage disease type Ia. This milestone expands its portfolio of treatments for r... Full story

Yahoo Finance • last month

Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease

Ultragenyx Pharmaceutical Inc. At Week 96, participants across treatment and crossover groups experienced mean reduction in daily cornstarch intake of 61% while maintaining glycemic control, with most participants achieving reduction of a... Full story

Yahoo Finance • last month

4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects

Rare diseases have moved steadily from being an overlooked corner of medicine to an important frontier for drug innovation. The FDA estimates that more than 7,000 rare diseases affect more than 30 million Americans, while most of these con... Full story

Yahoo Finance • 2 months ago

Ultragenyx (RARE) Jumped 7.5% on FDA Approval. Can a $2.7 Million Gene Therapy Become a Commercial Success?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was up 7.5% in after-hours trading as of approximately 5:33 p.m. ET Wednesday after the FDA approved Genglycos for glycogen storage disease type Ia, or GSDIa. The one-time gene therapy is the fi... Full story

Yahoo Finance • 2 months ago

Premarket movers: Deere jumps following upbeat Q3, Wolfspeed plunges

Investing.com - U.S. stock futures were little changed on Thursday, as a rally in government bonds lost momentum and investors assessed a fresh batch of corporate earnings and analyst actions. By 05:58 ET (09:58 GMT), Dow futures had fall... Full story

Yahoo Finance • 2 months ago

Biggest stock movers Thursday: Crypto stocks, WOLF, and more

[Woman at home investing in the stock market using an app on her tablet] ToucanStudios Stock futures were lower early Thursday as persistent geopolitical tensions in the Middle East drove Brent crude over $92 a barrel, reinforcing broader... Full story

Yahoo Finance • 3 months ago

Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update

NOVATO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic disea... Full story

Yahoo Finance • 3 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., July 24, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today repo... Full story

Yahoo Finance • 3 months ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Ultragenyx Pharmaceutical Inc. (RARE)

SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) against certain of its officers and directo... Full story

Yahoo Finance • 4 months ago

Institutional Confidence in GTX-102 Fuels Optimism for Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 21, Cantor Fitzgerald analyst Kristen Kluska maintained an Overweight rating on Ultragenyx Pharmaceuti... Full story

Yahoo Finance • 4 months ago

What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year

Key Points Krensavage bought 241,245 Ultragenyx Pharmaceutical shares last quarter. The quarter-end position value increased by $4.75 million, reflecting both trading and share price changes. The trade represented a roughly 2% increase in... Full story